Lightwave Logic Receives Notice of Allowance for Chromophore Architecture Patent

Lightwave Logic, Inc. (OTC Bulletin Board: LWLG), a technology company focused on the development of the 'Next Generation Electro-Optic Polymer Material Platform' for applications in high speed fiber-optic data communications and optical computing, announced that it has received a Notice of Allowance in U.S. Patent Application No. 11/666,320 for Heterocyclical Chromophore Architectures, which is directed to various Perkinamine™ chromophores, the company's base chromophore architecture -- the foundation of its unique electro-optic materials platform.

A chromophore is an advanced type of dye that imparts electro-optical properties to a polymer.  Perkinamine™ chromophores are a highly potent class of compounds which impart unparalleled thermal and optical stability to a resulting polymer matrix.

Jim Marcelli, Chief Executive Officer of Lightwave Logic said, "We are very pleased that after thorough prosecution at the USPTO we have received this Notice of Allowance for all seven pending claims. Protection of our Intellectual Property together with our know-how creates enormous value for our shareholders.

It is important to understand that our growing patent portfolio now includes allowed U.S. claims covering many of Lightwave's major compounds which individually can be used in a myriad of electro-optical devices and applications among them being; spatial modulators, amplitude and phase modulators, optical limiters, and optical computers."

Dave Eaton, the company's Chief Technology Officer stated, "Our base chromophore architecture is a powerful component of our advanced next generation electro-optical polymer platform. Together with our previously announced Notice of Allowance for our unique spacer, we now have strengthened protection for the total package required for advanced electro-optic applications in telecom and optical computing applications."

Source: http://www.lightwavelogic.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.